1. Distinctive CD39 + CD9 + lung interstitial macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis.
- Author
-
Han S, Kim B, Hyeon DY, Jeong D, Ryu J, Nam JS, Choi YH, Kim BR, Park SC, Chung YW, Shin SJ, Lee JY, Kim JK, Park J, Lee SW, Kim TB, Cheon JH, Cho HJ, Kim CH, Yoon JH, Hwang D, and Ryu JH
- Subjects
- Humans, Animals, Mice, Female, Male, Lung immunology, Lung pathology, Macrophages immunology, Macrophages metabolism, Mice, Inbred C57BL, Antigens, CD, Asthma immunology, Asthma metabolism, Neutrophils immunology, Neutrophils metabolism, Th17 Cells immunology, Th17 Cells metabolism, Interleukin-23 metabolism, Interleukin-23 immunology, Apyrase metabolism, Extracellular Traps metabolism, Extracellular Traps immunology, Tetraspanin 29 metabolism, Tetraspanin 29 genetics
- Abstract
The IL-23-Th17 axis is responsible for neutrophilic inflammation in various inflammatory diseases. Here, we discover a potential pathway to inhibit neutrophilic asthma. In our neutrophil-dominant asthma (NDA) model, single-cell RNA-seq analysis identifies a subpopulation of CD39
+ CD9+ interstitial macrophages (IMs) suppressed by IL-23 in NDA conditions but increased by an IL-23 inhibitor αIL-23p19. Adoptively transferred CD39+ CD9+ IMs suppress neutrophil extracellular trap formation (NETosis), a representative phenotype of NDA, and also Th17 cell activation and neutrophilic inflammation. CD39+ CD9+ IMs first attach to neutrophils in a CD9-dependent manner, and then remove ATP near neutrophils that contribute to NETosis in a CD39-dependent manner. Transcriptomic data from asthmatic patients finally show decreased CD39+ CD9+ IMs in severe asthma than mild/moderate asthma. Our results suggest that CD39+ CD9+ IMs function as a potent negative regulator of neutrophilic inflammation by suppressing NETosis in the IL-23-Th17 axis and can thus serve as a potential therapeutic target for IL-23-Th17-mediated neutrophilic asthma., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF